【24h】

The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice.

机译:躁郁症患者的管理:证据的审查及其与临床实践的整合。

获取原文
获取原文并翻译 | 示例
           

摘要

Bipolar disorder is a common, debilitating, chronic illness that emerges early in life and has serious consequences such as long-term unemployment and suicide. It confers considerable functional disability to the individual, their family and society as a whole and yet it is often undetected, misdiagnosed and treated poorly. In the past decade, many new treatment strategies have been trialled in the management of bipolar disorder with variable success. The emerging evidence, for pharmacological agents in particular, is promising but when considered alone does not directly translate to real-world clinical populations of bipolar disorder. Data from drug trials are largely based on findings that identify differences between groups determined in a time-limited manner, whereas clinical management concerns the treatment of individuals over the life-long course of the illness. Considering the findings in the context of the individual and their particular needs perhaps best bridges the gap between the evidence from research studies and their application in clinical practice. Specifically, only lithium and valproate have moderate or strong evidence for use across all three phases of bipolar disorder. Anticonvulsants, such as lamotrigine, have strong evidence in maintenance; whereas antipsychotics largely have strong evidence in acute mania, with the exception of quetiapine, which has strong evidence in bipolar depression. Maintenance data for antipsychotics is emerging but at present remains weak. Combinations have strong evidence in acute phases of illness but maintenance data is urgently needed. Conventional antidepressants only have weak evidence in bipolar depression and do not have a role in maintenance therapy. Therefore, this paper summarizes the efficacy data for treating bipolar disorder and also applies clinical considerations to these data when formulating recommendations for the management of bipolar disorder.
机译:躁郁症是一种常见的,令人衰弱的慢性疾病,在生命的早期出现,并带来严重的后果,例如长期失业和自杀。它给个人,他们的家庭和整个社会带来了相当大的功能障碍,但是却常常未被发现,误诊和治疗不善。在过去的十年中,在治疗躁郁症中尝试了许多新的治疗策略,但取得了不同的成功。新兴的证据,特别是对于药理学的药物,是有希望的,但是当单独考虑时,并不能直接转化为双相情感障碍的实际临床人群。药物试验的数据主要基于发现,这些发现可确定以限时方式确定的各组之间的差异,而临床管理则涉及疾病终生过程中对个体的治疗。考虑到个体的情况及其特定需求的结果,可能最好地弥合了研究证据与它们在临床实践中的应用之间的鸿沟。具体而言,只有锂和丙戊酸盐具有在双相情感障碍的所有三个阶段中使用的中度或强度证据。拉莫三嗪等抗惊厥药在维持治疗方面有很强的证据。而抗精神病药在急性躁狂症中有很强的证据,而喹硫平除外,后者在双相抑郁症中有很强的证据。抗精神病药的维护数据正在出现,但目前仍然薄弱。组合在疾病的急性期有很强的证据,但迫切需要维护数据。常规抗抑郁药仅在双相抑郁症中证据不足,在维持治疗中没有作用。因此,本文总结了治疗双相情感障碍的功效数据,并在制定双相情感障碍治疗建议时将临床考虑因素应用于这些数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号